SCHEMBL19974329

SCHEMBL19974329

Cc1ccc(CN2CCNCC2)c(C2(C(=O)O)CCCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.40
GRIN2B Q13224 2/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
OPRD1 P41143 2/20 0.38
OPRK1 P41145 2/20 0.38
GAA P10253 2/20 0.38
KDM5C P41229 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRL1 P41146 1/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.37
CHRM2 P08172 1/20 0.37
SLC6A4 P31645 1/20 0.37
CHRM3 P20309 1/20 0.37
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30395985 1.00 CXCR4 (0.40) CXCR4GRIN2BLMNAKDM4EALDH1A1
SCHEMBL30396354 0.79 MGLL (0.45) GRIN2BALDH1A1TP53CHRM2CHRM3
SCHEMBL19992807 0.76 MGLL (0.62)
SCHEMBL20151866 0.75 MGLL (0.48) CXCR4GRIN2BLMNAKDM4EALDH1A1
SCHEMBL19974349 0.74 ALDH1A1 (0.44) GRIN2BLMNAKDM4EALDH1A1OPRD1
SCHEMBL19386356 0.74 LMNA (0.44) CXCR4GRIN2BLMNAKDM4EALDH1A1
SCHEMBL28986035 0.73 KDM5C (0.49) CXCR4GRIN2BLMNAKDM4EALDH1A1
SCHEMBL28303843 0.73 DDR1 (0.42) OPRD1OPRK1OPRM1OPRL1
SCHEMBL22542165 0.72 LMNA (0.63) CXCR4GRIN2BLMNAALDH1A1OPRD1
SCHEMBL23774589 0.71 CHRM3 (0.44) CXCR4KDM4ECHRM2CHRM3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109996790-B Piperazine carbamates and methods of making and using the same H.隆德贝克有限公司 2023-05-16 CN disclosed
EP-3515897-B1 PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE H LUNDBECK AS (DK) 2021-08-18 EP disclosed
EP-3515897-B1 PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE H LUNDBECK AS (DK) 2021-08-18 EP disclosed
US-10899737-B2 Piperazine carbamates and methods of making and using same LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-01-26 US disclosed
EP-3515897-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2019-07-31 EP disclosed
US-20190202801-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2019-07-04 US disclosed
US-20190202801-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2019-07-04 US disclosed
WO-2018053447-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME ABIDE THERAPEUTICS, INC. (US) 2018-03-22 WO disclosed
WO-2018053447-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME ABIDE THERAPEUTICS, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10899737-B2 Piperazine carbamates and methods of making and using same ABHD6, RABL6, ABHD16A CXCR4 3758/4885GRIN2B 2109/4885LMNA 4625/4885
US-20190202801-A1 PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME ABHD6, RABL6, ABHD16A CXCR4 3758/4885GRIN2B 2109/4885LMNA 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.